Apremilast (CC-10004) has been trialled for use in psoriasis and psoriatic arthritis. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis;Fiona E McCann, Andrew C Palfreeman, Melanie Andrews, Dany P Perocheau, Julia J Inglis, Peter Schafer, Marc Feldmann, Richard O Williams and Fionula M Brennan;Arthritis Research & Therapy 2010, 12:R107